British Journal of Surgery, ISSN 0007-1323, 01/2019, Volume 106, Issue 2, pp. e103 - e112
Background The World Health Organization (WHO) Surgical Safety Checklist has fostered safe practice for 10 years, yet its place in emergency surgery has not...
SURGERY | IMPLEMENTATION | BARRIERS | HEALTH | Elective Surgical Procedures - statistics & numerical data | Prospective Studies | World Health Organization | Humans | Middle Aged | Patient Safety - statistics & numerical data | Checklist - statistics & numerical data | Male | Survival Rate | Laparotomy - mortality | Digestive System Surgical Procedures - statistics & numerical data | Elective Surgical Procedures - mortality | Emergency Treatment - statistics & numerical data | Emergency Treatment - mortality | Adult | Female | Aged | Digestive System Surgical Procedures - mortality | Cohort Studies | Laparotomy - statistics & numerical data | Original
SURGERY | IMPLEMENTATION | BARRIERS | HEALTH | Elective Surgical Procedures - statistics & numerical data | Prospective Studies | World Health Organization | Humans | Middle Aged | Patient Safety - statistics & numerical data | Checklist - statistics & numerical data | Male | Survival Rate | Laparotomy - mortality | Digestive System Surgical Procedures - statistics & numerical data | Elective Surgical Procedures - mortality | Emergency Treatment - statistics & numerical data | Emergency Treatment - mortality | Adult | Female | Aged | Digestive System Surgical Procedures - mortality | Cohort Studies | Laparotomy - statistics & numerical data | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article